Ubisol-Aqua™: Coenzyme Q10 prevents antiretroviral toxic neuropathy in an in vitro model

Current HIV Research

Volumn 8, Issue 3, 2010, Pages 232-239

  Cherry, Catherine L ^a,b,c   Mobarok, Masqura ^a   Wesselingh, Steven L ^a,b,c   Fain, Randi ^d   Weinstock, Shelley ^d   Tachedjian, Gilda ^a,c   Srivastava, Seema ^a   Tyssen, David P ^a   Glass, Jonathan D ^e   Hooker, David J ^a  

^a BURNET INSTITUTE   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d Zymes LLC   (United States)

^e EMORY UNIVERSITY   (United States)

Author keywords

Acetyl L carnitine; Coenzyme Q10; HIV; Neuropathy; Stavudine

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LEVACECARNINE; STAVUDINE; UBIDECARENONE; UBISOL AQUA; UNCLASSIFIED DRUG; ACETYLCARNITINE; DRUG DERIVATIVE; UBIQUINONE; VITAMIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; MITOCHONDRIAL TOXICITY; NERVE FIBER GROWTH; NEUROPATHY; NEUROTOXICITY; NONHUMAN; RAT; SPINAL GANGLION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; CELL SURVIVAL; DRUG EFFECT; NERVE CELL; ORGAN CULTURE TECHNIQUE;

ACETYLCARNITINE; AIDS-ASSOCIATED NEPHROPATHY; ANIMALS; ANTI-RETROVIRAL AGENTS; CELL SURVIVAL; DIDANOSINE; GANGLIA, SPINAL; NEURONS; ORGAN CULTURE TECHNIQUES; RATS; STAVUDINE; UBIQUINONE; VITAMINS;

EID: 77954037636     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016210791111106     Document Type: Article

References (36)

1. Cherry C, McArthur J, Hoy J, Wesselingh S. Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 2003; 26(2): 195-207.
2. Forna F, Liechty C, Solberg P, et al. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda. J Acquir Immune Defic Syndr 2007; 44(4): 456-62.
3. Smyth K, Affandi J, McArthur J, et al. Prevalence and risk factors for HIV-associated neuropathy in Melbourne, Australia 1993-2006. HIV Med 2007; 8 (6): 367-73.
4. Famularo G, Moretti S, Marcellini S, et al. Acetyl-carnitine deficiency in AIDS patients on treatment with antiretroviral neucleoside analogues. AIDS 1997; 11: 185-90.
5. Simpson D, Kalzenstein D, Haidich B, et al. Plasma carnitine in HIV-associated neuropathy. AIDS 2001; 15(16): 2207-8.
6. Scarpini E, Sacliotto G, Baron P, Cusini M, Sacarlato G. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients. J Peripher Nerv Syst 1997; 2(3): 250-2.
7. Youle M, Osio M, Group AS. A double-blind, parallel-group, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8: 241-50.
8. Hart A, Wilson A, Montovai C, et al. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS 2004; 18: 1549-60.
9. Fagher B, Thysell H, Nilsson-Ehle P, et al. The effect of D,Lcarnitine supplementation on muscle metabolism, neuropathy, cardiac and hepatic function in hemodialysis patients. A pilot study. Acta Med Scand 1982; 212(3): 115-20.
10. Bianchi G, Vitali G, Caraceni A, et al. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 2005; 41(12): 1746-50.
11. Sima A, Ristic H, Merry A, et al. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996; 97(8): 1900-7.
12. Quatraro A, Roca P, Donzella C, Acampora R, Marfella R, Giugliano D. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia 1995; 38(1): 123.
13. Malone J, Lowitt S, Salem A, Miranda C, Korthals J, Carver J. The effects of acetyl-L-carnitine and sorbinil on peripheral nerve structure, chemistry, and function in experimental diabetes. Metabolism 1996; 45(7): 902-7.
14. Fagher B, Cederblad G, Eriksson M, et al. L-carnitine and haemodialysis: double blind study on muscle function and metabolism and peripheral nerve function. Scand J Clin Lab Invest 1985; 45(2): 169-78.
15. Sima A, Calvani M, Mehra M, Amato A. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28(1): 89-94.
16. Galpern W, Cudkowicz M. Coenzyme Q treatment of neurodegenerative diseases of aging. Mitochondrion 2007; 7(Suppl): S146-S53.
17. Young A, Johnson S, Steffens D, Doraiswamy P. Coenzyme Q10: a review of its promise as a neuroprotectant. CNS Spectr 2007; 12(1): 62-8.
18. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57: 397-404.
19. Rabing-Christensen E, Stegger M, Jensen-Fangel S, Laursen A, Ostergaard L. Mitochondrial DNA levels in fat and blood cells from patients with lipodystrophy or peripheral neuropathy and the effect of 90 days of high-dose Coenzyme Q treatment: a randomized, double-blind, placebo-controlled pilot study. Clin Infect Dis 2004; 39: 1371-9.
20. Keswani S, Chander B, Hasan C, Griffin J, McArthur J, Hoke A. FK506 is neuroprotective in a model of antiretroviral toxic neuropathy. Ann Neurol 2003; 53(1): 57-64.
21. Kakuda T. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Therapeut 2000; 22: 685-708.
22. Stein DE, Moore KH. Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians. Pharmacotherapy 2001; 21(1): 11-34.
23. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985; 229(4713): 563-6.
24. Adachi A, Gendelman H, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986; 59(2): 284-91.
25. Wapling J, Moore K, Sonza S, Mak J, Tachedjian G. Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J Virol 2005; 79(16): 10247-57.
26. Tachedjian G, Mellors J, Bazmi H, Birch C, Mills J. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. J Virol 1996; 70(10): 7171-81.
27. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20(4): 309-21.
28. Moore RD, Wong W-ME, Keruly JC, McArthur JC. Incidence of neuropathy in HIV-infected patients on monotherapy vs those on combination therapy with didanosine, stavudine and hydroxyurea. AIDS 2000; 14: 273-8.
29. Wright E, Brew B, Arayawichanon A, et al. Neurological disorders are prevalent in HIV positive outpatients in the Asia- Pacific Region. Neurology 2008; 71: 50-6.
30. Konchalard K, Wangphonpattanasiri K. Clinical and electrophysiologic evaluation of peripheral neuropathy in a group of HIV-infected patients in Thailand. J Med Assoc Thai 2007; 90(4): 774-81.
31. Affandi J, Price P, Imran D, Yuhaningsih E, Djauzi S, Cherry C. Can we predict neuropathy risk before stavudine prescription in a resource limited setting? AIDS Res and Hum Retroviruses 2008; 24(10): 1281-4.
32. Herzmann C, Johnson M, Youle M. Long-term effect of acetyl-Lcarnitine for antiretroviral toxic neuropathy. HIV Clin Trials 2005; 6(6): 344-50.
33. Rosenfeldt F, Mijch A, McCrystal G, et al. Skeletal myopathy associated with nucleoside reverse transcriptase inhibitor therapy: potential benefit of coenzyme Q10 therapy. Int J STD AIDS 2005; 16(12): 827-9.
34. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals. Drug Safety 1998; 19(6): 481.
35. Sadler M, Nelson M. Peripheral neuropathy in HIV. In J STDs AIDS 1997; 8(1): 16-22.
36. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in Human Immunodeficiency Virus infection. J Acquir Immune Defic Syndr 1995; 9: 153-61.